Skip to main content
. 2010 Nov;33(11):2399–2405. doi: 10.2337/dc10-0493

Figure 1.

Figure 1

Mean change from baseline to month 12 in (A) BCVA and (B) CRT of the study eye: data for pooled ranibizumab doses (0.3–0.6 and 0.5–1.0 mg) versus sham. Full analysis set, LOCF. (Ranibizumab by-dose data are found in supplementary Fig. 4A and B, available in an online appendix.)